Mylan's Agila Challenge: FDA Throws Down the Glove
This article was originally published in RPM Report
The Food & Drug Administration’s September 9 warning letter to one of the eight Agila production facilities that Mylan is set to take control of by the end of this year shows both the depth of process issues that need to be cleaned up and the relatively good standing of the Agila facility vis-à-vis some of the other Indian facilities the FDA has recently visited.
You may also be interested in...
US FDA asks oncology drug sponsors for information on the impact of modifications to clinical trials during the pandemic – with close attention to remote monitoring and data collection.
AstraZeneca devoted a surprisingly large piece of its testimony at the recent House vaccine hearing to its therapeutic work. The company appears to be anticipating another shift in public attention back to the mAB cocktail as a way to treat and prevent COVID-19.
The efforts to upgrade FDA’s information technology infrastructure may be opening up into an opportunity to reinvent its processes for regulatory decision making.